Acolbifene

From WikiMD's Wellnesspedia

Acolbifene structure

Acolbifene (INN), with developmental code names EM-652 and SCH-57068, is a nonsteroidal selective estrogen receptor modulator (SERM). As of 2015, it was in advanced stages of clinical testing for its potential application in the treatment of breast cancer.

Pharmacology[edit | edit source]

Mechanism of Action[edit | edit source]

Acolbifene operates as a selective estrogen receptor modulator (SERM). SERMs are a group of compounds that bind to estrogen receptors in the body. Depending on the tissue type, they can either inhibit or activate estrogen-like actions. In the context of breast cancer, Acolbifene is expected to inhibit the estrogenic stimulation of cancer cells, potentially limiting the growth and proliferation of such cells.

Development[edit | edit source]

Pre-clinical Studies[edit | edit source]

Prior to advancing to human trials, Acolbifene underwent extensive pre-clinical testing. These tests aimed to determine its pharmacological properties, potential therapeutic benefits, and safety profile.

Clinical Trials[edit | edit source]

By 2015, Acolbifene had progressed to phase III clinical trials. This phase of clinical testing evaluates the drug's effectiveness, monitors side effects, and compares it to commonly used treatments for the targeted condition, in this case, breast cancer.

Potential Therapeutic Use[edit | edit source]

Breast Cancer Treatment[edit | edit source]

Breast cancer remains one of the most prevalent forms of cancer globally. The potential application of Acolbifene in its treatment is of significant interest to the medical community. Given its mechanism of action, Acolbifene could offer an alternative or supplemental approach to current breast cancer treatments, especially for cases driven by estrogenic stimulation.

See Also[edit | edit source]

External links[edit | edit source]


Acolbifene Resources

Find a healthcare provider anywhere in the world quickly and easily!

Wiki.png

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD


Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.


Contributors: Prab R. Tumpati, MD